Kura Oncology, Inc. (KURA): Price and Financial Metrics


Kura Oncology, Inc. (KURA)

Today's Latest Price: $29.66 USD

3.14 (-9.57%)

Updated Jan 27 3:40pm

Add KURA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 485 in Biotech

See all "A" rated Strong Buy stocks

KURA Stock Price Chart Interactive Chart >

Price chart for KURA

KURA Price/Volume Stats

Current price $29.66 52-week high $43.00
Prev. close $32.80 52-week low $6.35
Day low $29.51 Volume 782,676
Day high $32.60 Avg. volume 621,992
50-day MA $36.35 Dividend yield N/A
200-day MA $25.48 Market Cap 1.68B

Kura Oncology, Inc. (KURA) Company Bio


Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. The company was founded in 2014 and is based in La Jolla, California.


KURA Latest News Stream


Event/Time News Detail
Loading, please wait...

KURA Latest Social Stream


Loading social stream, please wait...

View Full KURA Social Stream

Latest KURA News From Around the Web

Below are the latest news stories about Kura Oncology Inc that investors may wish to consider to help them evaluate KURA as an investment opportunity.

What Is The Ownership Structure Like For Kura Oncology, Inc. (NASDAQ:KURA)?

If you want to know who really controls Kura Oncology, Inc. ( NASDAQ:KURA ), then you'll have to look at the makeup of...

Yahoo | January 25, 2021

Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling

SAN DIEGO--(BUSINESS WIRE)--With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina CEO, Francis deSouza, announced a series of oncology partnerships that aim to expan

Business Wire | January 11, 2021

Illumina CEO Says Business Is Bouncing Back. The Gene Sequencer Sees New Opportunities.

A leader in bringing down the costs of genetic sequencing sees opportunities for better diagnostics used to screen for cancers.

Yahoo | January 11, 2021

Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference

– Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb –

GlobeNewswire | January 7, 2021

Kura Oncology to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, January 12, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The virtual conference will be held from January 11-14, 2021. A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.About Kura OncologyKura Oncology is a clinical-stage biopharmaceu...

Yahoo | January 6, 2021

Read More 'KURA' Stories Here

KURA Price Returns

1-mo -12.84%
3-mo -7.17%
6-mo 80.41%
1-year 144.52%
3-year 48.67%
5-year 517.92%
YTD -9.19%
2020 137.53%
2019 -2.07%
2018 -8.24%
2017 159.32%
2016 -29.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0026 seconds.